Dr. Shilpa Gupta from Cleveland Clinic shares her favorite Uromigos episode leading up to the second annual Uromigos: Live & Unplugged event taking place in Nashville, Tennessee on November 3rd and 4th.
Advertisement
Latest News
The use of a SABR boost followed by chemoradiation to the pelvis was found to be well-tolerated in patients with MIBC.
Long-term DFS was noninferior in hypofractionated radiotherapy compared with conventional radiotherapy.
Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC.
A recent study adds to the scant literature on preclinical bladder autotransplantation before a first-in-human trial.
Precision medicine navigators increase the likelihood that Black patients with prostate cancer will receive genomic testing.
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation.
Intermediate-risk PC can be treated as effectively with SBRT as with conventional radiation, according to 5-year results.
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Trends were seen in shrinkage of PD-L1, inflamed tumors or tumors with high mutational burden, and immune-excluded tumors.
The median OS was 42.1 months in patients who received olaparib plus abiraterone and 34.7 months in placebo plus abiraterone.
These findings provide further support for identifying genes to better aid disease management in patients with PCa.
Patients considering PC screening should talk to their PCP or urologist about the benefits and risks of identifying PC early.
Expert Interviews
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
The use of a SABR boost followed by chemoradiation to the pelvis was found to be well-tolerated in patients with MIBC.
Long-term DFS was noninferior in hypofractionated radiotherapy compared with conventional radiotherapy.
Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC.
Precision medicine navigators increase the likelihood that Black patients with prostate cancer will receive genomic testing.
Video Insights
Clinical discussions with experts in the field